Immunological and genomic characterization of Ibizan Hound dogs in an endemic *Leishmania infantum* region

Luis Álvarez, Pablo‑Jesús Marín‑García and Lola Llobat*

**Abstract**

**Background:** The Ibizan Hound is a canine breed native to the Mediterranean region, where leishmaniosis is an endemic zoonosis. Several studies indicate low prevalence of this disease in these dogs but the underlying molecular mechanism remains unknown.

**Methods:** In this study, qualitative immunological and genomic profiles of this breed have been analyzed.

**Results:** Our analysis shows relevant differences between the cytokine serum profile of Ibizan Hound dogs and previously published data from other canine strains. Additionally, several genetic risk variants related to the immune response, regulation of the immune system, and genes encoding cytokines and their receptors have been studied. The most relevant genes that presented such fixed polymorphisms were *IFNG* and *IL6R*. Other variants with frequencies ≥ 0.7 were found in the genes *ARHGAP18*, *DAPK1*, *GNAI2*, *MITF*, *IL12RB1*, *LTBP1*, *SCL28A3*, *SCL35D2*, *PTPN22*, *CIITA*, *THEMIS*, and *CD180*. Epigenetic regulatory genes such as *HEY2* and *L3MBTL3* showed also intronic polymorphisms.

**Conclusions:** Our analysis and results indicate that the regulation of immune responses is different in Ibizan Hounds compared to other breeds. Future studies are needed to elucidate whether these differences are related to the low prevalence of *L. infantum* infection in the Ibizan Hound.

**Keywords:** Cytokines, Genetic regulation, Genomic analysis, Ibizan Hound, Immune response

---

**Background**

The Ibizan Hound, also named “Podenco Ibicenco” or “Ca Eivissenc,” is the oldest of the 32 Spanish dog breeds officially recognized by the Spanish Kennel Club and the “Federation Cynologique Internationale.” The Federation classified the Ibizan Hound breed with the standard number 89, in group 5-Sect. 7 (Spitz and primitive types-primitive type hunting dogs), being accepted, without working trial in Spain since 1954, with an official valid standard since 1982 and official genealogical book since 2007 [1].

Although the Ibizan Hound breed is native to the Balearic Islands, it is also quite abundant in other Mediterranean regions in Spain such as Catalonia or Valencia, and in France, such as Roussillon or Provence. According to The American Kennel Club, the main physical characteristics of the Ibizan Hound are: (i) height ranging between 23.5 and 27.5 inches in males and 22.5 and 26 inches in females; (ii) weight ranging between 45 and 50 pounds in both males and females; (iii) mean life expectancy ranging between 11 and 14 years in both sexes [1].

Hunting dogs have an increased risk of infectious disease transmission due to (i) direct or indirect contacts with wildlife reservoirs, (ii) exposure to vector insects and ticks, and (iii) feeding habits like entrail ingestion in areas where downed game animals are field dressed [2]. Leishmaniosis is considered one of the most relevant
vector-borne diseases in the Mediterranean region, where it is zoonotic, and its seroprevalence is estimated between 63 and 80% of the domestic dog population [3, 4], causing around 20,000–40,000 deaths per year in humans [5]. This disease is caused by different species of the genus *Leishmania*, including *L. infantum*, the most prevalent causal agent of leishmaniosis in the Mediterranean area, which is transmitted by *Phlebotomus* spp. [6].

The global seroprevalence in domestic dogs in Spain is estimated in 10.1%, one of the highest incidences in the Mediterranean region [7]. In a recent study from Llobat’s group exploring 26 canine breeds, not including Ibizan Hounds, estimated the prevalence of *L. infantum* infection in the Ibizan Islands to be 4.7% (positive animals with or without clinical signs), being the most prevalent in the Doberman Pinscher and Boxer breeds, with seroprevalences of 42.9% and 39.1%, respectively [8].

Several studies have shown differences in immune response against *L. infantum* infection in Ibizan Hounds. Burhnam et al. [9] found higher concentrations of anti-*Phlebotomus perniciosus* antibodies in saliva and concomitant increase of interferon-γ (IFN-γ) serum levels in Ibizan Hounds compared to other canine breeds. Therefore, it has been proposed that such high IFN-γ values have a protective effect, since they induce the cellular immune response [10]. Moreover, Solano-Gallego et al. (2000) demonstrated a different specific immune response against *L. infantum* in Ibizan Hound specimens compared to other canine breeds, showing that 81% of Ibizan Hound dogs analyzed presented a cellular immune response vs. only 48% presented in the other dogs [11].

In addition, some genomic analyses suggest that several polymorphisms are involved in the molecular mechanisms associated with the resistance or susceptibility to canine leishmaniosis. Two polymorphisms present in the canine *Slc11a1* gene, one intronic single-nucleotide polymorphism (SNP) and one silent SNP in exon 8, have been associated with an increased risk of canine visceral leishmaniosis [12]. Four SNPs in the canine β-defensin-1 (*CBD1*) gene have been associated with *L. infantum* infection in dogs from Italy [13].

As far as we know, no genomic studies in Ibizan Hound have been performed focusing on the immune response against *L. infantum*. Here, we present an immunological and genetic characterization of the Ibizan Hound breed to shed light on the underlying mechanisms leading to different immune responses.

**Methods**

**Animal and epidemiological data**

Twenty-eight Ibizan Hounds were analyzed. For all animals, epidemiological data were collected: sex, age, general and leishmaniosis vaccination status, external deworming status and type, living conditions (indoors or outdoors), type of parasitic feeding burden, and clinical signs.

**Sample collection and cytokine levels**

Ten milliliters of whole blood was taken by cephalic venipuncture using Vacutainer tubes without anticoagulant. Samples were maintained at room temperature to obtain serum aliquots, which were stored at −20°C until processing. Serological testing for *L. infantum* detection of specific antibodies was performed using the indirect immunofluorescent antibody test (IFAT) for anti-*Leishmania*-specific immunoglobulin G (IgG) antibodies (MegaFLUO® LEISH, Megacor Diagnostik GmbH, Hörbranz, Austria). Samples were considered seropositive with IFAT titer ≥ 1/80, following the manufacturer’s instructions. The whole blood samples were used for DNA extraction before 24 h to recovery.

The IL-2, IL-6, IL-8, IFN-γ (Canine IL-2 ELISA kit, Canine IL-6 ELISA kit, Canine IL-8 ELISA kit, and Canine IFN-γ ELISA kit, respectively; Invitrogen, Waltham, MA, USA), and IL-18 (Canine IL-18 ELISA kit, Mybiosource, San Diego, CA, USA) levels were measured in serum samples by commercial ELISA kit method following the manufacturers’ recommendations. In brief, 50 µl serum was used for the sandwich ELISA analysis. The microplate had been pre-coated with an antibody specific to cytokines. The samples were added to the microplate wells and combined with the specific antibody. Then, a biotinylated detection antibody specific for each cytokine and avidin-horseradish peroxidase (HRP) conjugate were added successively to each microplate well and incubated. Free components were washed away. The substrate solution was added to each well. The enzyme-substrate reaction was determined by the optical density (OD) and measured spectrophotometrically at a 450-nm wavelength in a Victor-X3™ plate reader (Perkin Elmer®). The concentration of each cytokine was calculated by comparing the OD of the samples to the standard curve.

**DNA extraction and whole genome analysis**

Genomic DNA (gDNA) from 28 Ibizan Hound samples was isolated using a QIAamp DNA Blood Kit following the manufacturer’s protocol (QIAamp; Qiagen, Hilden, Germany). DNA was quantified using a Nanodrop spectrophotometer (Thermo Fisher Scientific), and only samples with A<sub>260</sub>/A<sub>280</sub> ratio > 1.8 were used. gDNA concentrations for all samples were a minimum of 50 ng/µl. DNA samples were whole genome amplified for 20–24 h at 37°C, fragmented, precipitated and resuspended in an appropriate hybridization buffer.
Samples were genotyped using the CanineHD DNA Analysis BeadChip WG-440–1001 (Illumina, Inc., San Diego, CA, USA) and hybridized on the prepared BeadChips for 16–24 h at 48 °C. Following the hybridization, nonspecifically hybridized samples were removed by washing, while the remaining specifically hybridized loci were processed for the single-base extension reaction, stained, and imaged on an Illumina iScan Reader. GenomeStudio 2.0.5 (Illumina Inc., San Diego, CA, USA) was used to process data generated from the iScan system for subsequent analysis, according to manufacturer guidelines. Intensity data were loaded into the Genotyping Module to primary data analysis, including raw data normalization, clustering, and genotype calling.

SNPs on sexual chromosomes and with a call rate <95% were discarded using PLINK v1.90b6.22. The final data set included 165,480 mapped positions in 24 Ibizan Hound samples with a mean genotyping rate of 0.988.

Analysis of polymorphisms related to immune response
The allelic status of previously published polymorphisms and genomic regions described as related to the immune response to L. infantum infection in dogs [12, 14–19] were interrogated in the analyzed samples.

PLINK v1.90b6.22 was used to extract variants from the selected genome regions, encompassing 38 genes, according to the mapping information of the Canis lupus familiaris genome assembly CanFam3.1, and to calculate allele frequencies. Polymorphisms were considered fixed in the Ibizan Hound breed when presenting frequencies > 0.7. Detected polymorphisms were annotated using NCBI refseqs, release 105. The rsID information was downloaded and annotated from the European Variation Archive EVA release 3 files corresponding to the CanFam3.1 assembly.

Results
First, we studied relevant epidemiological parameters of the Ibizan Hound such as gender, age, and diet; 60.71% of the analyzed Ibizan Hound specimens were males, categorized as adults (32.14%) or elderly (39.29%). Most (82.14%) were fed commercial food (Table 1). According to their lifestyle, all animals lived outdoors in contact with other dogs, used external deworming, and had the required vaccinations. None of the subjects were vaccinated against Leishmania. Likewise, none of the animals included in this study presented a positive result for antibodies against Leishmania according to the IFAT technique. Serum levels of the analyzed cytokines are summarized in Table 2.

Second, we investigated the incidence of genomic variance in our cohort. In Tables 3, 4 and Additional file 1, information on 217 polymorphisms has been analyzed in 38 immune response-related genes. Table 3 summarizes the cytokine genes variants found in the genomic positions and their frequencies in the analyzed samples. In the IFN-γ gene, which is encoded by a gene located at chromosome 10, one polymorphism (rs22078594) was found with a frequency of 0.86 of the alternative alleles (A). In the IL2 gene, located at chromosome 2, a different variant was identified (rs22707631) in 3' UTR with a 0.63 frequency of the alternative allele. No variants were found in the IL6 gene in chromosome 14; however, the gene that encodes its receptor, located at chromosome 7, showed two variants. The first variant rs24423644 in the 19:17,756,202 position was the most relevant (frequency of the alternative allele = 1) and the second rs24416159 in 7:42,902,063 position (frequency of the alternative allele = 0.78).

Polymorphisms in genes other than cytokines were also found in the analyzed samples. More precisely, intronic variants have been found in Rho GTPase Activating Protein 18 (ARHGAPI8), Death Associated Protein Kinase 1 (DAPK1), G Protein subunit Alpha 2 (GNAI2), and Melanocyte Inducing Transcription Factor (MITF)
genes, some of them with alterative allele frequency of 1. Other intronic and downstream polymorphisms have been found in different genes which encode for other interleukin receptors (IL12RB1), interleukin regulators such as Latent Transforming Growth Factor-β binding protein (LTBP1), two members of Solute Carrier Family (SCL28A3 and SCL35D2), and Protein Tyrosine Phosphatase Non-Receptor Type 22 (PTPN22), several genes related to expression gene regulation by epigenetic mechanisms (HEY2, LMBTL3, and HABP4), membrane transport (ECHDC1 and RASEF), and immune system regulators (CIITA, THEMIS, and CD180), among others (Table 4). The results presented in Table 4 show those fixed variants in the population studied. The remaining SNPs were found with lower frequencies (additional file 1: Table S1).

**Discussion**

Our results show the immunological and genomic profile of the Ibizan Hound, which is the oldest of the 32 Spanish dog breeds officially recognized by the Spanish Kennel Club. In our analysis, several cytokine levels were compared to those previously published indicating a differential immunological profile. For the first time, serum levels of IL-2, IL-8, and IL-18 are studied in this canine breed.

Previous studies have indicated that the Ibizan Hound has a natural genetic resistance against leishmaniosis due to the early activation of the cellular immune response related to specific cytokines [11, 17, 20]. In fact, our results showed high levels of IFN-γ, IL-2, and IL-18, whereas the serum levels of IL-8 in this breed were lower than in other breeds [21]. The activation of macrophages by IFN-γ has been associated with effective T helper 1 (Th1) cellular immunity and the elimination of intracellular amastigotes and the control of the disease [11]. In the Ibizan Hound dogs [9] a higher expression level of IFN-γ was observed in animals positive to the leishmanin skin test (LST) than in dogs with healthy skin in the nonendemic area [22].

Moreover, the upregulation of IFN-γ has been correlated with low disease severity [23]. Furthermore, stimulation with Leishmania infantum soluble antigen (LSA) in Ibizan Hound dogs provokes higher IFN-γ serum levels than in other healthy or sick dog breeds [24]. The IFNG gene is located at chromosome 10 and presents four exons that codify a unique protein with 166 amino acids. Genomic analyses of IFNG show a fixed variant 10:10408724G>A (rs22078594) in an intronic region. This polymorphism produces a transcript named IFNG-201 with no associated biological functions [25]. However, since another intronic variant in IFNG has been correlated with both low levels of IFN-γ in humans and susceptibility to cutaneous leishmaniasis [26], more studies on the rs22078594 variant will be needed to elucidate its potential role in the regulation of the immune response.

The host ability to control Leishmania infection requires a strong cellular immune response, which is associated with the activation of T helper (Th)-1 cells producing IFN-γ and IL-2 [27, 28]. Additional evidence suggest that both factors have a key protective role in response to Leishmania infection [22, 29, 30]. Aslan et al. [34] found that IL-2 expression was negatively correlated with splenic parasite loads in experimentally infected dogs [31]. Our results are in agreement with previous data, indicating a natural resistance against leishmaniosis in Ibizan Hounds compared to other canine breeds [11, 24, 32]. The gene encoding for IL-2 is located at chromosome 19 and presents four exons. The variant found in the IL2 gene 19:17756202 T>C (rs22707631), overlaps one transcript of this gene [33]. This polymorphism is in the 3′-UTR region of the gene, which could have

---

**Table 3** Genomic variants found in genes encoding analyzed cytokines and their receptors

| Gene encodes cytokine, receptor, or gene related | rsID          | Chromosome position | Ref.–alt. | Frequency | Functional class of variant |
|-------------------------------------------------|---------------|---------------------|-----------|-----------|----------------------------|
| IFN-γ (IFNG)                                    | rs22078594    | 10:10,408,724       | G–A       | 0.86      | Intronic                   |
| IL-2 (IL2)                                      | rs22707631    | 19:17,756,202       | T–C       | 0.63      | 3′UTR                      |
| IL-6 receptor (IL6R)                            | rs24423644    | 7:42,878,605        | C–T       | 1.00      | 3′UTR                      |
| IL-6 cytokine family signal transducer (IL6ST)  | rs24416159    | 7:42,902,063        | G–A       | 0.78      | Intrinsic                   |
|                                                  | rs2433326     | 7:42,888,754        | T–C       | 0.22      | Intrinsic                   |
| IL-6 cytokine family signal transducer (IL6ST)  | rs22868191    | 2:43,260,700        | T–C       | 0.15      | Intrinsic                   |

Table shows the variant identification (rsID), chromosome position, reference and alternative alleles, frequency of alternative variant in the analyzed samples (those with frequencies > 0.7 are highlighted in bold) and functional class of variant

1 IFN-γ: interferon gamma, IL: interleukin
2 C: cytosine, T: thymine; A: adenine; G: guanine
| Gene     | rsID          | Chromosome position | Ref.-alt. | Frequency | Functional class of variant |
|----------|---------------|---------------------|-----------|-----------|-----------------------------|
| AEED1    | rs21889091    | 1: 70,201,861       | G-A       | 1         | Intronics                   |
| ARHGAP18 | rs21879501    | 1: 68,152,162       | G-A       | 1         | Intronics                   |
|          | rs22026852    | 1: 68,221,142       | T-C       | 0.96      | Intronics                   |
|          | rs21954955    | 1: 68,225,797       | T-C       | 0.93      | Intronics                   |
|          | rs9165143     | 1: 68,178,311       | C-T       | 0.76      | Intronics                   |
|          | rs21905342    | 1: 68,254,443       | T-C       | 0.71      | Intronics                   |
|          | rs21948539    | 1: 68,258,523       | T-C       | 0.70      | Intronics                   |
| CD180    | rs22872722    | 2:52,660,671        | T-C       | 0.77      | 3’UTR                       |
| CIITA    | rs24353887    | 6:31,796,528        | A-G       | 1.00      | Intronics                   |
|          | rs24328818    | 6:31,803,906        | T-C       | 0.96      | Intronics                   |
| CLVS2    | rs21898983    | 1: 62,276,253       | C-T       | 0.80      | Intronics                   |
| DAPK1    | rs21900944    | 1: 72,367,869       | G-A       | 0.78      | Intronics                   |
| ECHDC1   | rs21938035    | 1: 66,013,856       | A-G       | 0.87      | Intronics                   |
| GNAI2    | rs22932270    | 20:39,083,622       | G-C       | 0.96      | Intronics                   |
| GOLM1    | rs21950391    | 1: 73,631,884       | T-C       | 0.76      | Intronics                   |
| HABP4    | rs21886036    | 1: 70,370,888       | T-A       | 0.91      | Intronics                   |
| HEY2     | rs9207199     | 1: 64,638,097       | C-A       | 0.91      | Intronics                   |
| IL12RB1  | rs22916906    | 20:44,890,151       | C-T       | 0.78      | Intronics                   |
|          | rs22844706    | 20:44,906,998       | G-C       | 0.78      | Downstream                 |
| L3MBTL3  | rs21966134    | 1: 68,652,597       | T-C       | 0.83      | Intronics                   |
| LAMA2    | rs22024503    | 1: 7,706,395        | A-G       | 1         | Intronics                   |
|          | rs22040055    | 1: 67,843,651       | A-C       | 1         | Intronics                   |
|          | rs21975303    | 1: 68,074,486       | T-C       | 1         | Intronics                   |
|          | rs851817104   | 1: 67,689,922       | A-G       | 0.98      | Intronics                   |
|          | rs21912280    | 1: 67,694,283       | T-C       | 0.98      | Synonymous                  |
|          | rs21909819    | 1: 67,718,504       | T-C       | 0.92      | Intronics                   |
|          | rs21978490    | 1: 67,728,530       | A-G       | 0.92      | Intronics                   |
|          | rs21901417    | 1: 67,922,585       | G-A       | 0.73      | Intronics                   |
| LTBPI    | rs22600228    | 17:26,509,918       | C-T       | 1.00      | Intronics                   |
|          | rs22585937    | 17:26,469,383       | T-C       | 1.00      | Intronics                   |
|          | rs22565021    | 17:26,402,720       | C-T       | 1.00      | Intronics                   |
|          | rs22617477    | 17:26,375,163       | G-A       | 1.00      | Intronics                   |
|          | rs22564606    | 17:26,144,284       | C-T       | 0.98      | Intronics                   |
|          | rs22598552    | 17:26,233,826       | G-T       | 0.94      | Intronics                   |
|          | rs22583693    | 17:26,283,669       | G-A       | 0.92      | Intronics                   |
|          | rs22600112    | 17:26,478,030       | G-A       | 0.92      | Intronics                   |
|          | rs22585869    | 17:26,451,018       | C-G       | 0.87      | Intronics                   |
|          | rs22564554    | 17:26,133,100       | G-A       | 0.83      | Intronics                   |
|          | rs22584546    | 17:26,513,340       | T-C       | 0.79      | Intronics                   |
|          | rs22569416    | 17:26,520,738       | A-G       | 0.79      | Intronics                   |
|          | rs22600186    | 17:26,500,115       | C-T       | 0.73      | Intronics                   |
| MITF     | rs22864511    | 20:21,848,178       | A-C       | 1.00      | Intronics                   |
| PKIB     | rs21960517    | 20:21,848,178       | A-C       | 1.00      | Intronics                   |
| PTPN22   | rs22559491    | 17:51,651,794       | A-T       | 1.00      | Intronics                   |
|          | rs22559538    | 17:51,663,769       | G-A       | 1.00      | Intronics                   |
|          | rs22582077    | 17:51,667,891       | C-T       | 1.00      | Intronics                   |
|          | rs22559449    | 17:51,633,544       | A-G       | 0.90      | Intronics                   |
| PTPRK    | rs21887741    | 1: 66,895,650       | G-C       | 1         | Intronics                   |
|          | rs8721457     | 1: 66,692,393       | G-C       | 0.98      | Intronics                   |
Table 4 (continued)

| Gene | rsID     | Chromosome position | Ref-alt. | Frequency | Functional class of variant |
|------|----------|---------------------|----------|-----------|-----------------------------|
|      |          |                     |          |           |                             |
|      | rs22013934 | 1:66,866,914        | T-C      | 0.98      | Intronic                    |
|      | rs21951775 | 1:66,740,449        | A-G      | 0.98      | Intronic                    |
|      | rs21939204 | 1:66,833,054        | T-C      | 0.98      | Intronic                    |
|      | rs21951655 | 1:66,940,821        | G-T      | 0.80      | Intronic                    |
|      | rs22038850 | 1:66,626,458        | G-T      | 0.78      | Intronic                    |
|      | rs21963966 | 1:66,635,731        | C-T      | 0.78      | Intronic                    |
|      | rs21890648 | 1:66,648,882        | A-G      | 0.77      | Intronic                    |
|      | rs21914202 | 1:66,663,772        | C-T      | 0.77      | Intronic                    |
|      | rs8868883  | 1:66,673,590        | T-C      | 0.77      | Intronic                    |
|      | rs21893059 | 1:66,612,866        | C-T      | 0.76      | Intronic                    |
|      | rs9021755  | 1:6,599,857         | C-T      | 0.75      | Intronic                    |
|      | **RAB38** |          |          |           |                             |
|      | rs22921195 | 21:12,120,865      | T-C      | 1.00      | Intronic                    |
|      | rs22917843 | 21:11,811,693      | A-G      | 1.00      | Intronic                    |
|      | rs22976236 | 21:11,791,901      | G-A      | 0.96      | Intronic                    |
|      | **RASEF** |          |          |           |                             |
|      | rs21892604 | 1:76,327,161       | G-A      | 1.00      | Intronic                    |
|      | rs21894538 | 1:76,416,494       | C-T      | 1.00      | Intronic                    |
|      | rs21913661 | 1:76,423,140       | A-G      | 1.00      | Intronic                    |
|      | rs21984010 | 1:76,452,566       | G-A      | 1.00      | Missense                    |
|      | rs21965379 | 1:76,432,736       | C-T      | 0.98      | Intronic                    |
|      | rs21964231 | 1:76,456,202       | T-C      | 0.96      | Intronic                    |
|      | rs21969829 | 1:76,395,909       | C-T      | 0.92      | Intronic                    |
|      | **RSPO3** |          |          |           |                             |
|      | rs21964628 | 1:65,935,687       | G-C      | 1.00      | Intronic                    |
|      | rs8881600  | 1:65,858,997       | C-T      | 0.93      | Intronic                    |
|      | rs9173069  | 1:65,864,484       | T-C      | 0.85      | Intronic                    |
|      | rs22026455 | 1:65,912,368       | G-T      | 0.80      | Intronic                    |
|      | rs21975949 | 1:65,900,327       | C-T      | 0.77      | Intronic                    |
|      | rs92535550 | 1:65,884,205       | A-C      | 0.76      | Intronic                    |
|      | rs21978415 | 1:65,928,148       | G-A      | 0.76      | Intronic                    |
|      | **SLC2A3** |          |          |           |                             |
|      | rs9157044  | 1:75,042,990       | C-A      | 0.90      | Intronic                    |
|      | **SLC35D2** |          |          |           |                             |
|      | rs21998807 | 1:70,501,388       | A-G      | 0.94      | Intronic                    |
|      | **SERINC1** |          |          |           |                             |
|      | rs21937411 | 1:61,830,421       | G-T      | 1.00      | Missense                    |
|      | **THEMIS** |          |          |           |                             |
|      | rs21975824 | 1:66,376,836       | T-C      | 0.98      | Intronic                    |
|      | rs9237291  | 1:66,433,882       | C-T      | 0.98      | Intronic                    |
|      | rs9158578  | 1:6,416,081        | A-C      | 0.95      | 3’UTR                      |
|      | rs8659520  | 1:66,516,280       | A-G      | 0.95      | Intronic                    |
|      | rs21918658 | 1:66,399,264       | A-G      | 0.73      | Intergenic                  |
|      | **TF**    |          |          |           |                             |
|      | rs23149486 | 23:30,383,100      | A-T      | 1.00      | Intronic                    |

Table shows the identify number (rsID), chromosome position, reference and alternative alleles, frequency of alternative variant in the analyzed samples, and functional class of variant.

1. **AED1** (or **PRXL2C**): AhpC/TSA antioxidant enzyme domain containing 1 (or Peroxiredoxin like 2C); **ARGAP18**: Rho GTPase Activating Protein 18; **CIITA**: Class II Major Histocompatibility Complex Activator; **CLU52**: Clavesin; **DAPKI**: Death-Associated Protein Kinase I; **ECHDCT**: Enoyl-CoA Hydratase Domain-Containing Protein 1; **GNAI2**: G Protein Subunit Alpha I2; **GOLM1**: Golgi Membrane Protein 1; **HABP4**: Hyaluron Binding Protein 4; **HEY2**: Hes Related Family BHLH Transcription Factor with YRPW Motif 2; **I2R1B1**: Interleukin 12 receptor subunit Beta 1; **L3MBTL3**: L3MBTL Histone Methyl-Lysine Binding Protein 3; **LAMA2**: Laminin Subunit Alpha 2; **LIPF**: Latent Transforming Growth Factor Beta Binding Protein 1; **MITF**: Melanocyte Inducing Transcription Factor; **PKB**: CAMP-Dependent Protein Kinase Inhibitor Beta; **PTPN22**: Protein Tyrosine Phosphatase Non-Receptor Type 22; **PTPRK**: Protein Tyrosine Phosphatase Receptor Type K; **RAB38**: Member RAS Oncogene Family; **RASEF**: RAS and EF-Hand Domain Containing; **RSPO3**: R-Spondin 3; **SLC2A3**: Solute Carrier Family 2 Member 3; **SLC35D2**: Solute Carrier Family 35 Member D2; **SERINC1**: Serine Incorporator 1; **THEMIS**: Thymocyte Selection Associated; **TF**: Transferrin

2. C: cytosine; T: thymine; A: adenine; G: guanine
consequences in its post-transcriptional gene expression. In humans, several polymorphisms have been found in IL2, but it does not seem to predict susceptibility or protection against the development of disease to Leishmania guyanensis [34]. The biological changes associated with this variant are not reported in dogs or humans; thus, further studies will be necessary to shed light on the relationship between this 3’-UTR polymorphism and differences in serum levels of cytokines.

Additionally, IL-18 is a cytokine that plays an important role in both types of immunity, innate and acquired, and mediates Th1 response by inducing IFN-γ production in T cells and natural killer cells [35, 36]. Kumar et al. [40] found a significant relationship between susceptibility to visceral leishmaniasis in humans and the cytokine serum levels [37]. In dogs, it has been reported that IL-18 has no prominent role in the infection outcome of the disease [31, 38–41]. There is no evidence about the expression levels of IL-18 in different canine breeds, but similarly to IFN-g and IL-2, it is possible that IL-18 plays an important role in the natural resistance against leishmaniosis in Ibizan Hound dogs. Previous results from our group showed higher levels of IL-18 in Ibizan Hound than in the Boxer breed (data unpublished), which would be in agreement with these studies supporting the theory that the Ibizan Hound has a higher immune response against Leishmania than other canine breeds. IL18 gene is located at chromosome 5 and has seven exons. The array used for this study does not include any position in this gene, but it would be interesting to further analyze this gene and its genomic alterations to dissect whether they could regulate the elevated serum levels.

Low IL-8 serum level values were found in Ibizan Hound dogs. These results are consistent with the scarce studies focused on the role of IL-8 in Leishmania infection. Notably, IL-8 is an important cytokine for the activation of immune cells, especially neutrophils. Wardini et al. [45] found lower basal levels of IL-8 production in neutrophils in healthy dogs compared with infected animals [42]. A decrease in IL-8 levels has been reported in dogs infected both naturally and experimentally [43]. However, contrarily, it has been stated that amastigotes accumulate and survive in neutrophils in animals with high IL-8 levels [44], although these results are not conclusive. In humans, IL-8 polymorphism has been considered a risk factor for the development of visceral leishmaniasis [45].

Levels of the inflammatory cytokine IL-6 were similar to previously published data for other canine breeds [21]. Several authors found a higher expression of IL-6 in healthy than in experimentally infected sick dogs [20, 39]. Abbehusen et al. [46] demonstrated that serum levels of this cytokine increased in animals after natural and experimental infection [43]. De Lima et al. [49] pointed out that this cytokine is a good marker in active disease [46]. Other authors did not find a relationship between these cytokine levels and the development of leishmaniosis [31, 38]. The IL6 gene is located at chromosome 14 and presents five exons. No variants of this gene are included in the array. However, several SNPs have been found in the coding region of the IL-6 receptor (IL6R) and IL-6 cytokine family signal transducer (IL6ST) gene. For example, one SNP in 3’-UTR and one intronic polymorphism of IL6R are located at chromosome 7 and are fixed in the Ibizan Hound population studied. The 3’UTR variant results in a transcript named IL6R-201, which encodes a protein with 468 amino acids. The intronic polymorphism overlaps the same transcript as 3’UTR. Although these two SNPs are fixed in the Ibizan Hound population, their respective biological functions are largely unknown. Given that the results obtained in the serum levels of this interleukin were similar to those found in other canine breeds [21], it is possible that these variants do not influence them. IL-6 production increases in blood from dogs living in endemic areas of canine leishmaniosis cultured with several Toll-like receptors (TLR), in particular with TLR-4 and TLR-7a, but not with TLR-3a, whereas the IFN-γ production is not affected [47]. Other TLRs are related to L. infantum infection, so TLR-2 expression increases in mononucleate cells of the dermis with LST in Ibizan Hound dogs [48]. In human macrophages, the stimulation with agonist of TLR-2 increases the IFN-γ production through the PI3K-mTOR pathway [49]. In fact, in vitro studies have shown the ability of TLR-2 to reduce anti-leishmanial response mediated by IFN-γ [50], and TLR-2 is expressed in inflammatory cells such as biopsy samples of clinically affected skin [48]. The pathways of TLR and cytokines, and the relationship between them and their expression in macrophages of infected and non-infected dogs, and the polymorphisms of genes encoding these TLRs could be studied in future experiments to elucidate the mechanisms of resistance to L. infantum infection.

Different polymorphisms of several genes are fixed in the studied cohort of Ibizan Hound. Some are related to immune regulation. More precisely, six intronic SNPs with unknown biological function have been found in ARHGAP18 gene. This gene is related to regulation of lymphocyte-specific transcription factor interferon regulatory factor 4 (IRF4) [51]. Recently, Sundararaj and Casarotto [54] published a review indicating different functions of IRF4 in immune regulation, including B cell development [52]. Seven intronic variants are fixed in LAMA2 gene. Although LAMA2 is mainly related to muscular diseases (see editorial 70), some authors have indicated functions in immune response. For example, Lama2-deficient mouse model shows
elevated expression of proinflammatory cytokines, concretely, TNF-α and IL1β [53], and Li et al. [57] demonstrated that LAMA2 is a coreceptor to activate T cells upon infection by S. aureus [54]. Thirteen intronic polymorphisms have been found in LTBP1 gene, a known gene involved in T regulatory lymphocyte differentiation [14]. In fact, Batista et al. [14] performed a genome-wide association study of cell-mediated response in dogs infected by L. infantum, and their results showed several genetic markers, which explain the phenotypic variance in cytokines expression [14]. These genetic markers are in some genes where fixed variants have been identified in this study. For example, in LTBP1 and in IL12RB1, which is associated with TNF-α and involved in cytokine and chemokine signaling, with one intronic and downstream polymorphism fixed in our dog population. Another SNP fixed in the Ibizan Hound population and related to immune response is DAPK1 gene variant. DAPK1 protein is related to mTORC1 activation and CD8+ cell function, by a recently discovered mechanism and is necessary to antiviral activity [55, 56] and most likely antiparasitic immune response. Additionally, there are polymorphisms in known genes that regulate the immune response through other pathways, e.g. GNAI2, which regulates B cell motility and entrance into lymph nodes [57, 58], MITF, inhibitor of IL-1, IL-6, CCL-2, and TNF-α [59], PTPN22, a negative regulator of T cell receptor and B cell receptor signaling [60, 61], CIITA, a regulator of IL-6 and HLA-II expression [62, 63], and THEMIS, which encodes a protein necessary to maintenance of CD8+ T cell response and regulation of cytokine signal [64]. Two family members of Solute Carrier Family (SLC28A3 and SLC35D2) show intronic variants. Polymorphisms in other members of this family have been associated with susceptibility or resistance against visceral leishmaniosis in different dog populations [12, 65–68], probably by regulation of survival in host macrophages to parasite [69], which could be performed by other members of the same family. Finally, genes encoding regulatory proteins involved in epigenetic regulation also show fixed polymorphisms, such as HEY2, L3MBTL3, and HABP4. HEY2 is targeted by Notch1 in humans [70] and is involved in immune response activation [71]. Moreover, HEY2 expression is regulated by the same epigenetic pathway as NR4A1 [72], a key mediator of T cell dysfunction [73]. Notch signaling is also regulated by L3MBTL3 as epigenetic regulator [74]. Overall, our results indicate that Ibizan Hound is a canine breed with a singular immune response against L. infantum infection and probably against other pathogens. Therefore, further studies will be necessary to elucidate the molecular mechanism underlaying the immune response and its relationship with the low prevalence of leishmaniosis in this breed.

Conclusions

Several studies indicate that the Ibizan Hound seems to present resistance against L. infantum infection, with lower prevalence of leishmaniosis than other canine breeds. This qualitative study shows high levels of IFN-γ, IL-2, and IL-18 in Ibizan Hound dogs, whereas the serum levels of IL-8 in this breed are lower than in other breeds. The genomic analysis reveals many variants which are fixed in this dog population and related to expression and regulation of the immune system. These results indicate that this breed presents a specific immune response, which could explain this low prevalence of leishmaniosis and would be related to resistance against other infection pathogens. Future studies will be necessary to discover the specific biological function of the genetic SNPs found here, more precisely in genes related to expression and regulation of cytokines levels.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13071-022-05504-3. The online version contains supplementary material available at https://doi.org/10.1186/s13071-022-05504-3.

Additional file 1: Table S1. Genomic variants found in non-cytokine genes with frequency of alternative allele minor than 0.7. Table shows the identity number (rsID), chromosome position, reference and alternative alleles, frequency of alternative variant in the analyzed dataset, and functional class of variant.

Acknowledgements

We sincerely thank the ‘Podenco Ibicenco Association’ for allowing their data and samples of Ibizan Hound dogs. We are grateful to Dario Gabanes for the graphics, to Precision Medicine Unit of INCLIVA, and to the Veterinary Medicine Faculty of Universidad Cardenal Herrera-CEU.

Author contributions

Conceptualization, L.L.; methodology and formal analysis, L.A. and L.L.; data curation, P-J. M-G. and L.L.; writing—original draft preparation, L. A., P-J.M-G., and L.L.; writing—review and editing, L.L.; supervision, L.L.; project administration, L.L.; funding acquisition, L.L. All authors have read and agreed to the published version of the manuscript.

Funding

This work was funded by the grants for emerging research groups of Generalitat Valenciana (GV/2021/104). The funding agency was not involved in the design of the study, data collection, analysis of data or manuscript writing.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval

The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Animal Experimentation Ethics Committee of the Universidad Cardenal Herrera CEU (2020/0218). The owners of the dogs used in the study signed an informed consent for participation in the study.
Consent for publication
All authors agree with the The experiments involving animals were approved by the Animal Experimentation Ethics Committee of the Universidad Cardenal Herrera CEU with code 2020/VSC/PEA/0216 publication of manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 30 August 2022  Accepted: 21 September 2022 Published online: 28 November 2022

References
1. Ibiza Hound Dog Breeding Information. American Kennel Club. https://www.akc.org/dog-breeds/ibiza-hound/. Accessed on 30 May 2022.
2. Ridgway M. Hunting dogs. Vet Clin North Am Small Anim Pract. 2021;51:877–90.
3. Leontides LS, Saridomichelakis MN, Billinis C, Kontos V, Koutinas AF, Galatos AD, et al. A cross-sectional study of Leishmania spp. infection in clinically healthy dogs with polymerase chain reaction and serology in Greece. Vet Parasitol. 2002;109:19–27.
4. Mohabedi M, Malmasi A, Khodabakhsh M, Zarei Z, Akhoundi B, Hajarian H, et al. Feline leishmaniasis due to Leishmania infantum in Northwest Iran: the role of cats in endemic areas of visceral leishmaniasis. Vet Parasitol Reg Stud Rep. 2017;9:13–6.
5. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE. 2012;7:e35671.
6. González E, Molina R, Iriso A, Ruiz S, Aldea I, Tello A, et al. Opportunistic feeding behaviour and Leishmania infantum infection in Phlebotomus perniciosus females collected in the human leishmaniasis focus of Madrid, Spain. 2012–2018. PLoS Negl Trop Dis. 2021,15:e0009240.
7. Gálvez R, Montoya A, Cruz I, Fernández C, Martín O, Checa R, et al. Latest trends in Leishmania infantum infection in dogs in Spain, part I mapped sero-prevalence and sand fly distributions. Parasit Vectors. 2020;13:204.
8. Edo M, Marín-García PJ, Llobat L. Is the prevalence of Leishmania infantum linked to breeds in dogs? Characterization of seropositive dogs in Ibiza. Animals (Basel). 2021;11:2579.
9. Burtnam AC, Ordeix L, Alcover MM, Martínez-Orellana P, Montserrat-Sangrà S, Willem L, et al. Exploring the relationship between susceptibility to canine leishmaniosis and anti-Phlebotomus perniciosus saliva antibodies in dogs infected with other species of Leishmania. Vet Parasitol. 2009;20:37–45.
10. Abdelalim H, Kamhawi S, Valenzuela JG. What’s behind a sand fly bite? The profound effect of sand fly saliva on host hemostasis, inflammation and immunity. Infect Genet Evol. 2014;28:691–703.
11. Solano-Gallego L, Llull J, Álvarez-Fernández A, et al. The inflammatory cytokine effect of Leishmania infantum depots at bite sites. J Infect Dis. 2016;213:1752–61.
12. Batista LFS, Utsunomiya YT, Silva RB, Tomokane YT, et al. Genome-wide scan for visceral leishmaniasis in mixed-breed dogs identifies candidate genes involved in T cell helper cells and macrophage signaling. PLoS ONE. 2015;10:e0136749.
13. Alvar L, Francino O, Solano-Gallego L, Renier C, Sánchez A. Mapping and sequencing of the canine NRAMP1 gene and identification of mutations in leishmaniasis-susceptible dogs. Infect Immun. 2002;70:2763–71.
14. Martinez-Orellana P, Martí-Martorell D, Montserrat-Sangrà S, Ordeix L, Baneth G, Solano-Gallego L. Leishmania infantum-specific IFN-γ production in stimulated blood from dogs with clinical leishmaniasis at diagnosis and during treatment. Vet Parasitol. 2017;248:39–47.
15. Marín-García PJ, Llobat L. Canine cytokines profile in an endemic region of L. infantum: related factors. Vet Sci. 2022. https://doi.org/10.3390/vetsci10030035.
16. Ordeix L, Montserrat-Sangrà S, Martínez-Orellana P, Solano-Gallego L. Toll-like Receptors 2, 4, and 7, Interferon-gamma, interleukin 10, and programmed death ligand 1 transcripts in leishmanin skin test-positive reactions of Ibiza Hound dogs. J Immunol Res. 2020;2020:9602576.
17. Esteve LO. The spectrum of cutaneous manifestations in canine leishmaniosis: insights into diagnosis and immune responses. http://purl.org/ct/cdm/cityte/Text. Universitat Autonoma Barcelona. 2018.
18. Martinez-Orellana P, González N, Baldassarre A, Álvarez-Fernández A, Ordeix L, Paradies P, et al. Humoral responses and ex vivo IFN-γ production after canine whole blood stimulation with Leishmania infantum antigen or NMP112 recombinant protein. Vet Sci. 2022;9:116.
19. Transcript: ENSCAFT00845024391.1 (IFNG-201) - Variants - Canis lupus familiaris - Ensembl genome browser 107. http://www.ensembl.org/Canis_lupus_familiaris/Transcript/ProftVariations?id=core=ENSCAFT00845013680=105335241=105335241=105335241=vdf=variation;vdf=10918. Accessed on 13 Jul 2022.
20. da Silva GRL, Mesquita TG, Souza VC, Junior J, dos Santos Souza ML, Talhari AC, et al. A single haplotype of IFNg correlated with low circulating levels of interferon-γ is associated with susceptibility to cutaneous leishmaniasis caused by Leishmania guyanensis. Clin Infect Dis. 2020;71:274–81.
21. Maia C, Campbello L. Biomarkers associated with Leishmania infantum exposure, infection, and disease in dogs. Front Cell Infect Microbiol. 2018;8:302.
22. Maia C, Campbello L. Cytokine and phenotypic cell profiles of Leishmania infantum infection in the dog. J Trop Med. 2012;2012:541571.
23. Ordeix L, Montserrat-Sangrà S, Martínez-Orellana P, Baxiars M, Solano-Gallego L. Toll-like receptors 2, 4 and 7, interferon-gamma and interleukin 10, and programmed death ligand 1 transcripts in skin from dogs of different clinical stages of leishmaniasis. Parasit Vectors. 2019;12:575.
24. Carrillo E, Moreno J. Cytokine profiles in canine visceral leishmaniasis. Vet Immunol Immunopathol. 2009;128:67–70.
25. Asian H, Oliveira F, Meneses C, Castroviejo P, Gomes R, Teixeira C, et al. New insights into the transmissibility of Leishmania infantum from dogs to sand flies: experimental vector-transmission reveals persistent parasite deposits at bite sites. J Infect Dis. 2016;213:1752–61.
26. Martinez-Orellana P, Quirolo-Amores P, Montserrat-Sangrà S, Ordeix L, Llobat J, Álvarez-Fernández A, et al. The inflammatory cytokine effect of Pam3CSK4 TLR2 agonist alone or in combination with Leishmania infantum antigen on ex vivo whole blood from sick and resistant dogs. Parasit Vectors. 2017;10:123.
27. Martinez-Orellana P, Quirolo-Amores P, Montserrat-Sangrà S, Ordeix L, Llobat J, Álvarez-Fernández A, et al. The inflammatory cytokine effect of Pam3CSK4 TLR2 agonist alone or in combination with Leishmania infantum antigen on ex vivo whole blood from sick and resistant dogs. Parasit Vectors. 2017;10:123.
28. rs22707631 (SNP) - Explore this variant - Canis lupus familiaris - Ensembl genome browser 107. http://www.ensembl.org/Canis_lupus_familiaris/Transcript/ProftVariations?id=core=ENSCAFT00845033554=vrs=rs22707631vdf=variation;vdf=1375817. Accessed on 13 Jul 2022.
29. de Araujo FJ, da Silva LDO, Mesquita TG, Pinheiro SK, Vital WD, Chrusciak-Talhari A, et al. Polymorphisms in the TOLLIP gene influence susceptibility to cutaneous leishmaniasis caused by Leishmania guyanensis in the Amazonian State of Brazil. PLoS Negl Trop Dis. 2015. https://doi.org/10.1371/journal.pntd.0003875.
35. Okamura H, Kashiwamura S, Tsutsui H, Yoshimoto T, Nakanishi K. Regulation of interferon-gamma production by IL-12 and IL-18. Curr Opin Immunol. 1998;10:259–64.

36. Takeda K, Tsutsui H, Yoshimoto T, Adachi O, Yoshida N, Kishimoto T, et al. Defective NK cell activity and Th1 response in IL-12-deficient mice. Immunology. 1998;90:838–90.

37. Kumar D, Tiwary P, Chakravarty J, Sundar S. Association of interleukin-18 gene polymorphism with susceptibility to visceral leishmaniasis in endemic area of Bihar, an Indian population. ScientificWorldJournal. 2014;2014:852104.

38. Pinelli E, Killick-Kendrick R, Wagenaar J, Bernadina W, del Real G, Rutenberg J. Cellular and humoral immune responses in dogs experimentally and naturally infected with *Leishmania infantum*. Infect Immun. 1994;62:229–35.

39. Chamizo C, Moreno J, Alvar J. Semiquantitative analysis of cytokine expression in asymptomatic canine leishmaniasis. Vet Immunol Immunopathol. 2005;103:67–75.

40. Manera L, Reale S, Volta E, Vitale F, Foglia Manzillo V, Pavone LM, et al. *Leishmania* DNA load and cytokine expression levels in asymptomatic naturally infected dogs. Vet Parasitol. 2006;142:271–80.

41. Carrillo E, Ahmed S, Goldsmith-Pestana K, Nieto J, Osorio Y, Travi B, et al. Immunogenicity of the P-8 amastigote antigen in the experimental model of canine visceral leishmaniasis. Vaccine. 2007;25:1534–43.

42. Wardini AB, Pinto-da-Silva LH, Nadaves NR, Nascimento MT, Roat BM, Reis AB, et al. Neutrophil properties in healthy and *Leishmania infantum*-naturally infected dogs. Sci Rep. 2019;9:6247.

43. Abbehusen MMC, Almeida VDA, Solcà MdS, Pereira LdS, Costa DJ, Gil-Santana L, et al. Clinical and immunopathological findings during long term follow-up in *Leishmania infantum* experimentally infected dogs. Sci Rep. 2017;7:15914.

44. Sanz CR, Miró G, Sevane N, Reyes-Palomares A, Dunner S. Modulation of Host Immune Response during *Leishmania infantum* natural infection: a whole-transcriptome analysis of the popliteal lymph nodes in dogs. Front Immunol. 2021;12:794627.

45. Hajiilooi M, Abaii M, Bazmani A, Ahmadi A, Matini M, Solgi G, et al. Evaluation of interleukin-8 -251 t/a polymorphisms in visceral leishmaniasis. J Res Health Sci. 2015;15:59–61.

46. de Lima VMF, Peiro JR, de Oliveira VR. IL-6 and TNF-alpha production during active canine visceral leishmaniasis. Vet Immunol Immunopathol. 2007;115:189–93.

47. Martinez-Orellana P, Montserrat-Sangrà S, Quirola-Amores P, González N, Solano-Gallego L. Cytokine effect of TLR3, TLR4, and TLR7 agonists alone or associated with *Leishmania infantum* antigen on blood from dogs. Biomed Res Int. 2018;2018:5693736.

48. Oudeix L, Silva JEDS, Luilj J, Quirola P, Montserrat-Sangrà S, Martinez-Orellana P, et al. Histological and immunological description of the leishmanin skin test in Ibican Hounds. J Comp Pathol. 2018;158:56–65.

49. Gajanyaka N, Dong SKM, Ali H, Isbilal S, Mosokeereea J, Lawton DA, et al. TLR4 agonist induces IFN-γ production selectively in proinflammatory human M1 macrophages through the PI3k-mTOR- and JNK-MAPK-activated p70S6K pathway. J Immunol. 2021;207:2310–24.

50. Srivastava S, Pandey SP, Jha MK, Chandel HS, Saha B. Solute carrier family 11 member 1 (Slc11a1) activation efficiently inhibits *Leishmania donovani* survival in host macrophages. J Parasit Dis. 2017;41:671–7.

51. Bourdon M, Santulli R, Doridot L, Jeljeli M, Chêne C, Chouzenoux S, et al. NOTCH1 and DLL4 are involved in the human tuberculosis progression and immune response activation. Tuberculosis (Edinb). 2020;124:101980.

52. Wang L, Yao QZ, Moorman JP, Xu Y, Ning S. Gene expression profiling identifies IRF4-associated molecular signatures in hematological malignancies. PLoS ONE. 2014;9:e106788.

53. Sundararaj S, Casarotto MG. Molecular interactions of IRF4 in B cell development and malignancies. Biophys Rev. 2013;13:1219–27.

54. Jeudy S, Woodard KE, Alessi A, Dominov JA. Bcl-2 inhibits the innate immune response during early pathogenesis of murine congenital muscular dystrophy. PLoS ONE. 2011;6:e22369.

55. Li Z, Zeppa JJ, Hancock MA, McCormick JK, Doherty TM, Hendy GN, et al. Neutrophil properties in healthy and *Leishmania infantum*-naturally infected dogs. Vet Parasitol. 2006;142:271–80.

56. Wei Z, Li P, He R, Liu H, Liu N, Xia Y, et al. DAPK1 (death-associated protein kinase 1) mediates mTORC1 activation and antiviral activities in CD8+ T cells. Cell Mol Immunol. 2021;18:138–49.

57. Hwang I-H, Park C, Kehrl JH. Impaired trafficking of Gna2-/- and Gnaq2-/- T lymphocytes: implications for T cell movement within lymph nodes. J Immunol. 2007;179:439–48.

58. Han S-B, Moratz C, Huang N-N, Kessali B, Cho H, Shi C-S, et al. Rgs1 and Gna2 regulate the entrance of β lymphocytes into lymph nodes and B cell motility within lymph node follicles. Immunity. 2005;22:343–54.

59. Ballotti R, Cheli V, Bertolotto C. The complex relationship between MIF and the immune system: a melanoma immunotherapy (response) factor? Mol Cancer. 2020;19:1707.

60. Arechiga AF, Habib T, He Y, Zhang X, Zhang Z-Y, Funk A, et al. Cutting edge: the PTPPN22 allelic variant associated with autoimmunity impairs B cell signaling. J Immunol. 2009;182:3343–7.

61. Gjorgjio-Wrenig A, Saxena M, Williams S, Hammi D, Mustelin T. Characterization of TCR-induced receptor-proximal signaling events negatively regulated by the protein tyrosine phosphatase PEP. Eur J Immunol. 1999;29:3845–54.

62. Ramia E, Chiavaralli AM, Bou Nasser Eddine F, Tedeschi A, Sessa F, Accolla RS, et al. CIITA-related block of HLA class II expression, upregulation of HLA class I, and heterogeneous expression of immune checkpoints in hepatocarcinomas: implications for new therapeutic approaches. Oncoimmunology. 2017;6:e124603.

63. Adhikari A, Bokk B, Edington S, Becerra N, Kohli P, Pond A, et al. IFN-y and CIITA modulate IL-6 expression in skeletal muscle. Cytokine X. 2020;100:102993.

64. Brzostek J, Gautam N, Zhao X, Chen EW, Mehta M, Tung DWH, et al. T cell receptor and cytokine signal integration in CD8+-T cells is mediated by the protein Thems. Nat Immunol. 2020;21:186–98.

65. Sanchez-Robert E, Allet T, Sanchez A, Francino O. Polymorphism of Slc11a1 (Nrpmp1) gene and canine leishmaniasis in a case-control study. J Hered. 2005;96:755–8.

66. Braiiou GG, Kontou PI, Boleti H, Bagos PG. Susceptibility to leishmaniasis is affected by host Slc11a1 gene polymorphisms: a systematic review and meta-analysis. Parasitol Res. 2019;118:2329–42.

67. Egihal R, Hida M, Idissi ML, Hess HD, Lerner M. Slc11a1 polymorphisms and susceptibility to visceral leishmaniasis in Moroccan patients. Acta Trop. 2014;140:130–6.

68. Bueno R, Carvalho Neto AV, Xavier MN, Oliveira RG, Diniz SA, Melo MN, et al. CDAI sequencing and expression of Nrpmp1 (Slc11a1) in dogs phe notypically resistant or susceptible to visceral leishmaniasis. Vet Immunol Immunopathol. 2009;127:332–9.

69. Singh N, Gedda MR, Tiwari N, Singh SP, Bajpai S, Singh RK. Solute carrier protein family 11 member 1 (Slc11a1) activation efficiently inhibits *Leishmania donovani* survival in host macrophages. J Parasit Dis. 2017;41:671–7.

70. Bourdon M, Santulli R, Doridot L, Jeljeli M, Chêne C, Chouzenoux S, et al. Immune cells and Notch1 signaling appear to drive the epithelial to mesenchymal transition in the development of adenomyosis in mice. Mol Hum Reprod. 2021. https://doi.org/10.1093/molehr/gaab053.

71. Castro RC, Zambuzi FA, Fontanari C, de Morais FR, Bollela VR, Kunkel SL, et al. NOTCH1 and DLL4 are involved in the human tuberculosis progression and immune response activation. Tuberculosis (Edinb). 2020;124:101980.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.